Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Serum visfatin level in prediabetics and its relation to left ventricular function

The Egyptian Journal of Internal Medicine volume 31, pages 703–714 (2019)Cite this article

Abstract

Introduction

Visfatin is a molecule of clinical relevance, released mainly from visceral fat (hence it named as such) and could be a promising biomarker with diagnostic and prognostic significance in metabolic syndrome. Very little is known about visfatin and its relation with prediabetes.

Objective

The present study was conducted to demonstrate the relationship between serum visfatin level and prediabetes and its relation to left ventricular function.

Patients and methods

We studied 60 prediabetic patients recently diagnosed according to ADA criteria 2014 and classified into two groups according to the BMI. They were compared with 30 healthy matched controls. All groups underwent complete history taking, general examination, laboratory investigations (including homeostasis model assessment-insulin resistance and serum visfatin level), and two-dimensional transthoracic echo Doppler study at baseline and 8 months thereafter only for the patient groups.

Results

This study showed that there is a positive correlation between serum visfatin level and prediabetes and left ventricular function.

Conclusion

Serum visfatin is an early and strong predictor of prediabetes and left ventricular dysfunction.

References

  1. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307:426–430.

    Article  CAS  Google Scholar 

  2. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, Kang GB, et al. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyl transferase, free and in complex with the anti-cancer agent FK-866. Mol Biol 2006; 362:66–77.

    Article  CAS  Google Scholar 

  3. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113:1318–1327.

    Article  CAS  Google Scholar 

  4. Gastaldelli A, Basta G. Ectopic fat and cardiovascular disease: what is the link? Nutr Metab Cardiovasc Dis 2010; 20:481–490.

    Article  CAS  Google Scholar 

  5. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178:1748–1758.

    Article  CAS  Google Scholar 

  6. Flier JS, Flier EM. Biology of Obesity. In Wiener C, Fauci AS, Braunwald E, Kasper D, Hauser S, Longo D, et al. eds. Harrison’s principles of internal medicine. New York: The Mcgraw-Hill companies Inc; 2007; 462–472

    Google Scholar 

  7. Ye SQ, Simon BA, Maloney JP, Zambelli-Weiner A, Gao L, Grant A, et al. Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 2005; 171:361–370.

    Article  Google Scholar 

  8. Koczan D, Guthke R, Thiesen HJ, Ibrahim SM, Kundt G, Krentz H, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15:251–257.

    CAS  PubMed  Google Scholar 

  9. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15:1851–1862.

    Article  CAS  Google Scholar 

  10. Dedoussis GV, Kapiri A, Samara A, Dimitriadis D, Lambert D, Pfister M, et al. Visfatin: the link between inflammation and childhood obesity. Diabetes Care 2009; 32:e71.

    Article  Google Scholar 

  11. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, et al. Nampt/ PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6:363–375.

    Article  CAS  Google Scholar 

  12. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:295–299.

    Article  CAS  Google Scholar 

  13. López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55:2871–2875.

    Article  Google Scholar 

  14. Rosa P, Oliveria C, Gufferida F, Reis A. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010; 2:21–26.

    Article  Google Scholar 

  15. Abd Rabo SA, Mohammed NA, Eissa SS, Ali AA, Ismail SM, Gad RS. Serum visfatin in type 2 diabetes mellitus. Egypt J Intern Med 2013; 25:27–32.

    Google Scholar 

  16. Shelbaya S, Shoeib N, Seddik S, Makboul K, Abd El Baki R, Fahmy E, El-ghohary E. Study of the adipocytokine visfatin in obesity and type 2 diabetes mellitus. Endocrine 2011; 25:P160.

    Google Scholar 

  17. Chang YH, Chang DM, Lin KC, Shin SJ, Lee YJ. Visfatin in overweight/ obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review. Diabetes Metab Res Rev 2011; 27:515–527.

    Article  Google Scholar 

  18. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81:370–380.

    Article  CAS  Google Scholar 

  19. Torres C, Lima-Martínez MM, Rosa FJ, Guerra E, Paoli M, Iacobellis G. Epicardial adipose tissue and its association to plasma adrenomedullin levels in patients with metabolic syndrome. Endocrinol Nutr 2011; 58:401–408.

    Article  CAS  Google Scholar 

  20. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011; 22:450–457.

    Article  CAS  Google Scholar 

  21. Lima-Martínez MM, Blandenier C, Iacobellis G. Epicardial adipose tissue: more than a simple fat deposit?. Endocrinol Nutr 2013; 60:320–328.

    Article  Google Scholar 

  22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412–419.

    Article  CAS  Google Scholar 

  23. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458.

    Article  CAS  Google Scholar 

  24. Choi KM, Kim JH, Cho GJ, Baik SH, Park HS, Kim SM. Effect of exercise training on plasma visfatin and eotaxin levels. Eur J Endocrinol 2007; 157:437–442.

    Article  CAS  Google Scholar 

  25. Araki S, Dobashi K, Kubo K, Kawagoe R, Yamamoto Y, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. Obesity (Silver Spring) 2008; 16:384–388.

    Article  CAS  Google Scholar 

  26. Manco M, Fernandez-Real EAL JM, Equitani F, Vendrell J, Valera Mora ME, Nanni G, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007; 92:483–490.

    Article  CAS  Google Scholar 

  27. García-Fuentes E, García-Almeida JM, García-Arnés J, García-Serrano S, Rivas-Marín J, et al. Plasma visfatin concentrations in severely obese subjects are increased after intestinal bypass. Obesity (Silver Spring) 2007; 15:2391–2395.

    Article  Google Scholar 

  28. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fats, obesity, type 2 diabetes mellitus in Asian Indians. Metabolism 2007; 56:565–570.

    Article  CAS  Google Scholar 

  29. Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, et al. Reduced plasma visfatin/pre-B cell colony -enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab 2006; 91:3165–3170.

    Article  CAS  Google Scholar 

  30. Berndt J, Kloting N, Kralisch S, Kovacs P, Fasshauer M, Schon MR, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54:2911–2916.

    Article  CAS  Google Scholar 

  31. Esteghamati A, Alamdari A, Zandieh A, Elahi S, Khalilzadeh O, Nakhjavani M, Meysamie A. Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res Clin Pract 2011; 91:154–158.

    Article  CAS  Google Scholar 

  32. Gursoy G, Akcayoz SS, Acar Y, Demirbas B. Visfatin in hyperlipidemic female patients. J Med Med Sci 2010; 1:120–125.

    Google Scholar 

  33. Erten Y, Ebinç FA, Ebinc H, Pasaoglu H, Demirtas C, Tacoy G, et al. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Renal Fail 2008; 30:617–623.

    Article  CAS  Google Scholar 

  34. El-Shafey EM, El-Naggar GF, Al-Bedewy MM, El-Sorogy H. Is there a relationship between visfatin level and type 2 diabetes mellitus in obese and non obese patients? J Diabetes Metab 2012; S:11.

  35. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56:451–458.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Faculty of Medicine, Al-Azhar University, 77 El Daher Pebars Street, Cairo, Egypt

    Mohammed Abdel-Hassib MD Degree of Internal Medicine & Abdelhaleem A. Hassabo

  2. Department of Clinical Pathology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

    Hossam Elashmawy

  3. Department of Cardiology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt

    Mostafa I. S. Mansour

Authors
  1. Mohammed Abdel-Hassib MD Degree of Internal Medicine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdelhaleem A. Hassabo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossam Elashmawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mostafa I. S. Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammed Abdel-Hassib MD Degree of Internal Medicine.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdel-Hassib, M., Hassabo, A.A., Elashmawy, H. et al. Serum visfatin level in prediabetics and its relation to left ventricular function. Egypt J Intern Med 31, 703–714 (2019). https://doi.org/10.4103/ejim.ejim_119_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_119_19

Keywords